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ABSTACT 
The quantity of medication brought into the marketplace is growing each year. Analytical method development is increasingly being introduced into 
fundamental pharmaceutical research and pharmaceutical analysis practice, taking into account their high sensitivity, accuracy, specificity and 
expressiveness. Search criteria was analytical method development for medicines from group of ACE inhibitors. Literature survey has been done in 
range of years 1990-2018 to make the review updated and comprehensive and to show the new approacheches to the development of the methods of 
analysis ACE inhibitors. The sources were world recognized journals and key words used as filter were angiotensin-converting enzyme inhibitors, 
captopril, enalapril, method development, spectrophotometry, HPLC, UHPLC. The current review is created with an intended to focus on the advantage 
of HPLC. Literature survey revealed that a number of methods have been reported for estimation of ACE inhibitors individually or in combination with 
other drugs. However, there is very few analytical methods reported for the simultaneous analysis of these drugs in a combined dosage formulation by 
HPLC. In additional, analysis of approaches to the development of the methods of analysis of ACE inhibitors in drugs and biological liquids has been 
shown that HPLC is the most suitable method for analyses ACE inhibitors in substances, drugs, biological liquids to performe routine analysis of 
medicines, pharmacokinetic (bioequivalence in vivo), dissolution test for final dosages forms (bioequivalence in vitro, biowaiver procedure).  
Keywords: Angiotensin-converting enzyme inhibitors, Captopril, Enalapril, Spectrophotometry, HPLC, UHPLC, Pharmacokinetic, Bioequivalence 




Angiotensin-converting enzyme (ACE) inhibitors help relax blood 
vessels. ACE inhibitors prevent an enzyme in your body from 
producing angiotensin II, a substance in your body that narrows 
your blood vessels and releases hormones that can raise your blood 
pressure. This narrowing can cause high blood pressure and force 
your heart to work harder. Many ACE inhibitors are available. Which 
one is best for you depends on your health and the condition being 
treated. People with chronic kidney disease may benefit from having 
an ACE inhibitor as one of their medications.  
Since 1981, ACE inhibitors have been commonly prescribed to treat 
hypertension. This is because they tend to be well-tolerated by those 
who take them. They’re usually taken just once a day, often in the 
morning. They may be prescribed along with diuretics or calcium 
channel blockers, which are also used to treat high blood pressure. 
ACE inhibitors have two primary functions. First, they decrease the 
amount of sodium retained in the kidneys. Secondly, they stop the 
production of a hormone called angiotensin II. This hormone usually 
causes blood vessels to narrow. When this hormone isn’t produced, 
blood flows through the vessels more effectively. This helps the 
blood vessels to relax and expand, which lowers blood pressure [1]. 
The quantity of medication brought into the marketplace is growing 
each year. Physico-chemical analysis methods are increasingly being 
introduced into fundamental pharmaceutical research and 
pharmaceutical analysis practice, taking into account their high 
sensitivity, accuracy. Search criteria was analytical method 
development for medicines from group of ACE inhibitors. Literature 
survey has been done in range of years 1990-2018 to make the review 
updated and comprehensive and to show the new approacheches to 
the development of the methods of analysis ACE inhibitors. The 
sources were world recognized journals and key words used as filter 
were angiotensin-converting enzyme inhibitors, captopril, enalapril, 
method development, spectrophotometry, HPLC, UHPLC. 
Analytical method development of captopril 
Captopril is an angiotensin-converting enzyme (ACE) inhibitor used 
in the therapy of hypertension and heart failure. Captopril is 
associated with a low rate of transient serum aminotransferase 
elevations and has been linked to rare instances of acute liver injury 
[2]. Chemical name of captopril is (2S)-1-[(2S)-2-methyl-3-
sulfanylpropanoyl] pyrrolidine-2-carboxylic acid (fig. 1). 
 
 
Fig. 1: The chemical structures of captopril 
 
The State Pharmacopoeia of Ukraine (SPhU) has the monograph on 
the substance of captopril and on tablets of captopril [86-94]. For 
identification of captopril substance, the SPhU proposes to 
determine the specific optical rotation and the method of absorption 
spectrophotometry in the infrared region, the quantitative 
determination–iodometry potentiometric titration using the 
combined platinum electrode. For identification of captopril in 
tablets, the SPhU proposes TLC (mobile phase–a mixture of 
methanol P, ice acetic acid P, toluene P (1:25:75). For quantitative 
determination of captopril in tablets–HPLC/UV (mobile phase–a 
mixture of phosphoric acid of concentrated P, water P and methanol 
P (0.5:450:550), mobile phase rate–1.0 ml/min, detection of 
wavelength 220 nm). 
The United States Pharmacopeia regulates the definition of captopril 
in substances, tablets and combined tablets with 
hydrochlorothiazide. For identification of captopril in the substance, 
the method of absorption spectrophotometry in the infrared region 
and the determination of specific optical rotation is proposed, for 
quantitative determination–iodatometry. For the identification of 
captopril in tablets, the United States Pharmacopoeia offers TLC 
(mobile phase–analogue to the SPhU), for quantification–HPLC/UV. 
According to this monograph, the following chromatographic 
conditions are used: chromatographic column of category L1 (with 
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fixed phase C18) size 4.6 mm x 250 mm; mobile phase–methanol P: 
water P: phosphoric acid P (550:450:0.5); wavelength–220 nm, flow 
rate–1.0 ml/min. 
The European Pharmacopoeia suggests for identification of captopril 
substance to determine the specific optical rotation and the method 
of absorption spectrophotometry in the infrared region, the 
quantitative determination–iodometry, potentiometric titration with 
the use of a combined platinum electrode. 
Methods of quantitative determination of captopril in the drug and 
biological fluids by spectrophotometry and chromatography [3-25] 
methods are described in the scientific literature. 
Captopril has three analytical and functional groups in its structure 
(carboxyl group, keto group and mercapto group), which determine 
the methods of captopril analysis. Titrimetric methods have not 
been widely used in the analysis of medical form of captopril, since 
the drugs have auxiliary substances that would interfere with the 
determination of captopril titrimetrically in medical form. 
Spectrophotometric methods of analysis are widely used in the 
analysis of drugs containing captopril. The scientific literature 
describes methods for determining captopril by spectrophotometry 
using various reagents to determine the mercapto group. 
The authors S. M. El-Ashry, F. A. Ibrahim developed two 
spectrophotometric methods for the determination of captopril in 
tablets, which were based on the reactivity of thiol group. In the first 
method, promethazine hydrochloride during interaction with the 
solution of N-Bromophthalimide in orthophosphate acid was 
oxidized to the free radical of promethazine, which had a maximum 
absorption at 516 nm. Red color of promethazine was quantitatively 
reduced by captopril to colorless promethazine. Adding captopril to 
the red solution of promethazine resulted in reduction in absorption 
in direct proportion to the amount of captopril, which was the basis 
of spectrophotometric determination of captopril in tablets. The 
second method involved the use of molybdenum phosphoric acid as 
an oxidant to determine captopril. When captopril interacted with 
molybdenum phosphate acid, there was formed a reaction product 
of blue color during heating and the maximum of absorption was 
685 nm [3, 4].  
Jovanović T et al. proposed spectrophotometric determination of 
captopril in interaction with palladium (III) chloride in the Britton-
Robinson buffer solution at different pH values (2.14-9.10) with the 
formation of yellow reaction product with the maximum absorption at 
380 nm. Developed spectrophotometric method has been successfully 
applied for the determination of captopril in the drug [5]. 
Spectrophotometric method for the determination of captopril in the 
drug using 2,3-dichloro-1,4-naphthoquinone (dichloro) in a neutral 
environment with forming a product of yellow reaction with the 
maximum absorption at 347 nm is described by Dawood H. et al. [6, 7]. 
Scientists H. Chandru and A. C. Sharada developed a 
spectrophotometric method for the determination of captopril in the 
drug using hexacyanoferrate (III) as a reagent. Solutions of the 
complex have absorption maxima at 510 nm and are subject to the 
Bouguer-Lambert-Beer’s law in the concentration range of 0.25-
12.00 μg/ml. The proposed method has been successfully applied to 
determine this API in tablets [8]. 
Scientists A. Gumieniczek, D. Kowalczuk and L. Przyborowski 
proposed chromatographic and spectrophotometric methods of 
determination of captopril in tablets. The method of reverse 
HPLC/UV detection of captopril was developed using the 
chromatography column LiChrosorb RP-18 column, mobile phase–a 
mixture of phosphate buffer solution pH 2.4 and acetonitrile (7:3, 
v/v) at wavelength of 211 nm and internal standard–celiprolol. The 
spectrophotometric method was based on the interaction of 
captopril with tetrazolium blue with the formation of a product of 
blue reaction having a maximum absorption at 526 nm [9-14]. 
Jebaslinhepzybai B. et al. developed HPLC/UV method for captopril 
determination in tablets using the chromatography column LC1 
(C18) column (250 × 4.6 mm; 5μm) and mobile phase–a mixture of 
methanol and water (55:45 v/v), flow rate–1 ml/min, detection 
wavelength–220 nm. The method was linear in the range of 
concentrations of 80-120 μg/ml, the correlation coefficient was 
0.999. The developed method has been successfully applied for 
routine analysis of captopril in drugs [15]. 
Scientists Leanpolchareanchai J. and Suksiriworapong J. described 
the HPLC/UV method for the determination of captopril in 
extemporaneous medical form for use in pediatrics. In solution, 
captopril is oxidized to captopril disulfide, therefore the developed 
method involves the simultaneous determination of captopril and 
captopril disulfide in medical form. Chromatography was carried out 
using the mobile phase–a mixture of methanol and 0.1% phosphoric 
acid. Captopril holding time was 5.1-5.4 min and captopril 
disulphide–12.2-12.9 min. The method was linear in the 
concentration range 0.75-20 μg/ml, the correlation coefficient was 
0.9995. The developed method was fully validated [16]. 
Reverse-phase HPLC/UV method for the simultaneous 
determination of captopril with antagonists of H-2 histamine 
receptors (cimetidine, ranitidine, famotidine) was described by 
Sultan N. et al. The proposed method uses the chromatography 
column Purospher star C18 (5 μm, 250 mm × 4.6 mm) and mobile 
phase–a mixture of methanol, water and phosphate buffer solution 
pH 3.0 (60:40 v/v), mobile phase rate–0.8 ml/min, detection 
wavelength is 225 nm. Captopril holding time was 5.2 min. The 
method was linear in the range of concentrations of 9.3-150 μg/ml, 
correlation coefficient was 0.9993, LOD–1.75 ng/ml, LOQ–5.3 ng/ml. 
The developed method has been successfully applied to study the 
bioavailability of captopril in the presence of antagonists of H-2 
histamine receptors [17]. 
Huang T. et al. developed the reverse-phase HPLC/UV method for the 
simultaneous determination of captopril and hydrochlorothiazide in 
blood plasma using the chromatography column C(18) column 
(DIAMONSIL 150 mmx4 mm i.d., 5 microm) and mobile phase–a 
mixture of acetonitrile, fluoracetic acid and water in gradient elution 
mode, mobile phase rate–1.2 ml/min, detection wavelength is 263 nm. 
Captopril holding time was 6.8 min, hydrochlorothiazide–16.9 min, 
respectively. The method is linear in the range of concentrations of 
captopril 20-4000 ng/ml and hydrochlorothiazide–10-1200 ng/ml. 
The correlation coefficient of captopril was 0.9993, 
hydrochlorothiazide was 0.9999. LOQ of captopril was 7 ng/ml, of 
hydrochlorothiazide was 3.3 ng/ml, respectively. The developed 
method has been successfully applied for the determination of 
captopril and hydrochlorothiazide in blood plasma [18]. 
Scientists N. Sultana, MS Arayne, S. Naveed proposed HPLC/UV 
method for the determination of captopril and API from the group of 
nonsteroidal anti-inflammatory drugs (flurbiprofen, ibuprofen, 
diclofenac sodium, mefenamic acid) in drugs and blood plasma using 
the chromatography column Purosher star C18 (250 mmx4.6 mm id, 
5 microm) and mobile phase–a mixture of methanol, water, 
orthophosphoric acid pH 2.8 (80:20 v/v), mobile phase rate–1.0 
ml/min, detection wavelength–227 nm. LOD of captopril was 1 
ng/ml, whereas fluoxetine–0.2 ng/ml, ibuprofen 1 ng/ml, diclofenac 
sodium 2 ng/ml, mefenamic acid 0.4 ng/ml. LOQ of captopril was 3.5 
ng/ml, fluoropropene–0.9 ng/ml, ibuprofen–2.9 ng/ml, diclofenac 
sodium–8 ng/ml, mefenamic acid–1 ng/ml, respectively. The 
retention time of all analyzes was less than 12 min [19]. 
Scientists N. Aykin, R. Neal, M. Yusof, N. Ercal developed the method 
for the determination of captopril in biological fluids with ThioGlo 3 
derivatization due to the presence of thiol group. Captopril was 
derivatized by ThioGlo 3 [3H-naphtho [2,1-b]pyran,9-acetoxy-2-(4-
(2,5-dihydro-2,5-dioxo-1H-pyrrol-1yl)phenyl-3-oxo-)]. 
Chromatography was performed using the chromatography column 
Astec C (18) column and mobile phase–a mixture of water, 
acetonitrile, acetic acid, phosphoric acid (50:50, 1 ml/l of acids) per 
wavelength of excitation of 365 nm and wavelength of radiation of 
445 nm. The developed method was used to determine captopril in 
biological fluids [20, 21]. 
Li K. et al. described HPLC/UV method for the determination of 
captopril in blood plasma and the use of this method for the study of 
pharmacokinetics. The proposed method uses the chromatography 
column Spherisorb C18 column and mobile phase–a mixture of 
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water, acetonitrile, acetic acid (44:55:0.2, v/v/v), internal standard–
4-chloro-2-nitroaniline, detection wavelength–258 nm. Captopril 
holding time was 5.2 min. The method was linear in the range of 5-
500 ng/ml, LOD–2 ng/ml, Tmax–0.56 h, Cmax–266.5 ng/ml, AUC 
(zero)-infinity–380.3 ng/ml. The developed method was successfully 
applied for the study of pharmacokinetics [22-24]. 
Scientists Papanov S., Hadjieva B., N. Koleva developed the reverse-
phase HPLC/UV method for the determination of captopril in tablets 
using the chromatography column LiChrosorb® RP-18 (10 μm, 
250x4 mm) and mobile phase–a mixture of methanol and water 
(60:40% v/v) with the addition of phosphatic acid to pH 3.0, mobile 
phase rate–2.0 ml/min, column temperature–30 °C, detection 
wavelength–220 nm. Captopril holding time was 8 min. The method 
is linear in the range of concentrations of captopril 25-200 μg/ml, 
correlation coefficient–0.9997. LOD of captopril was 7 ng/ml, LOQ–
20 ng/ml, respectively. The developed method was successfully 
applied for the determination of captopril in drugs [25-47]. 
A simple, rapid, sensitive, and specific method was developed for the 
determination of captopril by UHPLC in mono-medicines and 
pharmaceutical dosage forms in combination with 
hydrochlorothiazide without previous separation. Satisfactory 
resolution was achieved using Fused-Core® technology Ascentis 
Express C18 column (4.6×150 mm) and a mobile phase consisting of 
methanol and 0.1% solution of trifluoroacetic acid (40/60, v/v) at a 
flow rate 1.2 ml/minute and the wavelength detection was 220 nm. 
Ascentis Express columns, based on Fusеd-core pаrticle technоlogy, 
prоvide more than twice the speed and efficiency of traditiоnal 
cоlumns at half the backpressure of sub-2-μm columns. Compared to 
the previous method [18], the retention time for captopril was 1.345 
min [28]. The shorter run-time of UHPLC methods results in 
reducing organic solvent volumes and the whole time of analysis, 
without decreasing the sensitivity and resolution of determination. 
Moreover, laboratory staff are less exposed to toxic agents and 
solvolysis of analytes caused by the presence of organic solvents is 
limited. Taking into consideration the above mentioned advantages 
UHPLC methods may be recommended for studies adopting a green 
approaches to pharmaceutical analysis of ACE inhibitors. 
 
 
Fig. 2: The chemical structures of enalapril 
 
Analytical method development of enalapril 
Enalapril is an angiotensin-converting enzyme (ACE) inhibitor 
widely used in the therapy of hypertension and heart 
failure. Enalapril is associated with a low rate of transient serum 
aminotransferase elevations and has been linked to rare instances of 
acute liver injury [2]. Chemical name of enapalril is (2S)-1-[(2S)-2-
[[(1S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl] pyro-
lidine-2-carboxylic acid (fig. 2). 
The State Pharmacopoeia of Ukraine (SPhU) has the monograph on 
the substance of enalapril maleate and on enalapril tablets. For 
identification of the substance of enalapril maleate, the SPhU offers 
the method of absorption spectrophotometry in the infrared region, 
quantitative determination–alkalimetry potentiometric titration. For 
identification of enalapril in tablets, the SPhU proposes TLC (mobile 
phase–a mixture of acetic acid of ice P, water P, butanol P (15:25:60). 
For the quantitative determination of enalapril in tablets–HPLC/UV 
(mobile phase–a mixture of acetonitrile P and solvent (40:60), 
solvent–potassium dihydrogen phosphate solution P, mobile phase 
rate–1.0 ml/min, detecting by wavelength at 215 nm). 
The United States Pharmacopeia regulates the determination of 
enalapril maleate in substances and tablets. For the identification of 
enalapril maleate in the substance, the method of absorption 
spectrophotometry in the infrared region and HPLC/UV, for the 
quantitative determination–HPLC/UV is proposed. For the 
identification and quantification of enalapril in tablets, the United 
States Pharmacopeia offers HPLC/UV. According to this monograph, 
the following chromatographic conditions are used: 
chromatographic column of category L1 (fixed phase C18) with size 
4.6 mm x 250 mm; mobile phase–a mixture of buffer solution 
(solution of sodium dihydrogen phosphate with the addition of 
phosphoric acid to pH2.2): acetonitrile P (75:25); wavelength–215 
nm, flow rate–2.0 ml/min. 
The European Pharmacopeia [3] suggests the method of absorbing 
spectrophotometry in the infrared region for the identification of 
substance enalapril maleate, quantitative determination–alkalimetry 
potentiometric titration. 
Methods of quantitative determination of enalapril maleate in drugs 
and biological fluids by methods of spectrophotometry and 
chromatography [48-75] are described in the scientific literature. 
Scientists Dubey S. K., Kumar S., Mudakavi R. J., Deshpande S. 
developed the UV-spectrophotometric method of enalapril maleate 
determination. The maximum absorption of enalapril–207 nm. The 
method was linear in the range of concentrations of 2-28 μg/ml and 
phosphate buffer solution pH 7.2. The developed method can be 
used in routine analysis of drugs containing enalapril maleate [48]. 
Ayad M. M. et al. described methods of spectrophotometric 
determination of enalapril and ramipril by formation of complexes. 
The complex compound (enalapril, eosin, cuprom (II)) was 
determined in two ways. The first method is the extraction of the 
complex compound with chloroform and determination of the 
optical substance at 533.3 nm. Subjection to the Bouguer-Lambert-
Beer’s law in the concentration range–56-112 μg/ml. The second 
method is direct measurement of the optical density at 558.8 nm 
after the addition of methyl cellulose at pH 5. Subjection to the 
Bouguer-Lambert-Beer’s law in the concentration range–19-32 
μg/ml. The proposed methods were successfully applied to 
determine enalapril and ramipril in medical form [49]. 
Baraka M. M. et al. proposed spectrophotometric methods for the 
determination of ramipril, enalapril, and fosinopril drugs, which 
were based on the formation of complex compounds in the 
interaction with molybdenum (V) thiocyanate, which was extracted 
with chloroform. The solutions of complex have absorption maxima 
at 517 nm and are subject to the Bouguer-Lambert-Beer’s law in the 
range of enalapril concentrations of 4-36 μg/ml, ramipril and 
fosinopril–10-90 μg/ml. Another way was direct determination of 
the complex compound after adding benzalkonium chloride as 
surfactant. Solutions of complex have absorption maxima at 545 nm 
and are subject to the Bouguer-Lambert-Beer’s law in the range of 
enalapril concentrations of 3-27 μg/ml, ramipril and fosinopril–8-72 
μg/ml. The developed methods were successfully applied for the 
determination of ramipril, enalapril, and fosinopril in drugs [50]. 
Scientists Ayad M. M., Shalaby A., Abdellatef H. E., Hosny M. M. 
developed spectrophotometric methods for determination of enalapril 
and timolol in drugs. The first method was based on the formation of a 
complex compound with palladium (II) chloride in buffer media, while 
the second method was the formation of colored complexes in 
interaction with palladium (II) salt, eosin and detectable APIs using 
methylcellulose as surfactant to increase the solubility of complex 
compounds. Solutions of complex have absorption maxima at 369.4 
nm of timolol and 362.8 nm–enalapril and are subject to the Bouguer-
Lambert-Beer’s law in the range of concentrations of timolol 20-200 
μg/ml and enalapril 50-300 μg/ml for the first method. The second 
method was more sensitive and the Bouguer-Lambert-Beer’s law was 
in the range of timolol concentrations 1.6-16 μg/ml and enalapril–8-56 
μg/ml, respectively. The developed spectrophotometric methods were 
successfully applied for the determination of timolol and enalapril in 
drugs [51, 52]. 
Sowjanya G. et al. described the spectrophotometric method of 
enalapril and hydrochlorothiazide determination in tablets. The 
maximum absorption of enalapril was observed in a deep ultraviolet 
with wavelength of 207 nm, and hydrochlorothiazide–272 nm. The 
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method was linear in the range of concentrations of enalapril 5-50 
μg/ml and hydrochlorothiazide–5-30 μg/ml, respectively [53, 54]. 
Scientists Rahman N., Manirul Haque S. K. developed 
spectrophotometric methods for determination of enalapril maleate 
in drugs. The first method was based on the interaction of enalapril 
with potassium iodate and potassium iodide to form a yellow 
reaction product with a maximum absorption at 352 nm. Other 
methods were based on the reaction of complexation with n-
chloranalic acid in environment of 1,4-dioxane methanol, from 2,2-
dichloro-5,6-dicyano-1,4-benzoquinone in environment of 
acetonitrile-1,4 dioxane, with potassium iodide in environment 
acetonitrile-dichloromethane. Subjection to the Bouguer-Lambert-
Beer’s law was in the range of concentrations of 2.5-50, 20-560, 5-75 
and 10-200 μg/ml, respectively. The developed methods were 
successfully applied for the spectrophotometric determination of 
enalapril maleate in drugs [55]. 
Simona Gherman et al. offered the spectrophotometric method of 
determination of enalapril maleate in drugs of different 
manufacturers. The method was based on the dissolution of enalapril 
in buffer solution of pH 4, the maximum absorption was observed at 
208 nm. The method was linear in the range of concentrations of 1-20 
μg/ml, LOD–0.3721 μg/ml, LOQ–0.9019 μg/ml [56]. 
Scientists Manindra M., Zafar H. S. and Ankur K. described HPLC/UV 
method for the determination of enalapril maleate in tablets using 
the chromatography column Hypersil MOS, 5μ (250 mm x 4.6 mm) 
and mobile phase–a mixture of buffer solution and acetonitrile 
(40:60, v/v), flow rate–1.5 ml/min, wavelength detection–215 nm. 
Enalapril holding time was 9.72 min. The method was linear in the 
range of concentrations of 150-250 μg/ml, correlation coefficient 
was 0.9992. The developed method was successfully applied for the 
control of the quality of drugs that contain enalapril maleate [57]. 
Scientists Al-Momani F. developed the HPLC/UV method for 
determination of enalapril maleate and hydrochlorothiazide in tablets 
using the chromatography column Supelcosil LC-8 (5 μm, 150 mm ×4.6 
mm i.d.), internal standard–theophylline and mobile phase–
tetrabutylammonium hydrogen sulfate in acetonitrile, water, 
tetraamine (14:85.6:6.4, v/v/v) with addition of ice acetic acid to pH 
4.1, detection wavelength–220 nm. The developed method was used to 
determine enalapril maleate and hydrochlorothiazide in drugs [58]. 
Reverse-phase HPLC/UV method for the simultaneous 
determination of enalapril maleate and hydrochlorothiazide in drugs 
was proposed by Suryadevara Vidyadhara et al. The developed 
method uses the chromatography column C18 column (ODS UG 
column 250 mm×4.5 mm) and mobile phase–a mixture of acetate 
buffer, methanol and acetonitrile (60:20:20 V/V/V, pH 5), mobile 
phase rate–0.8 ml/min, detection wavelength–232 nm. Enalapril 
maleate holding time was 2.8 min, hydrochlorothiazide–4.1 min. The 
method was linear in the range of concentrations of 10-30 μg/ml, 
correlation coefficient was 0.999, LOD enalapril–0.16 μg/ml, LOQ 
enalapril–0.49 μg/ml. The developed method was successfully 
applied for the determination of enalapril maleate and 
hydrochlorothiazide in drugs [59]. 
The scientist Bharat G. described the HPLC/UV method for 
determining enalapril maleate and amlodipine in drugs using the 
chromatography column Phenomenex C18 (5 μm, 250 mm × 4.6 
mm) and mobile phase–a mixture of methanol, acetonitrile, water 
(40:50:10, v/v/v), mobile phase rate–1.0 ml/min. Enalapril holding 
time was 2.27 min, amlodipine was 5.07 min. The method was linear 
in the enalapril concentration range of 0.5-6.0 μg/ml, correlation 
coefficient was 0.9989, LOD of enalapril–0.04 μg/ml, LOQ of 
enalapril–0.4 μg/ml. The method was linear in the amlodipine 
concentration range of 0.5-8.0 μg/ml, correlation coefficient was 
0.9983, LOD of amlodipine was 0.04 μg/ml, LOQ–0.4 μg/ml. The 
developed method was successfully applied for the determination of 
enalapril maleate and amlodipine in drugs [60]. 
Scientists Sultana N., Saeed A. and Naveed S. developed the method 
of reverse-phase HPLC/UV determination of enalapril maleate in the 
presence of API from the group of statins (rosuvastatin, atorvastatin, 
simvastatin). Chromatography was performed using the 
chromatographic column Purospher Star, C18 (5 mm, 250 x 4.6 mm) 
and mobile phase–a mixture of acetonitrile and water (60:40 v/v), 
detection wavelength–230 nm. The holding time of all analytes was 
less than 10 min. The method was linear in enalapril concentration 
range of 2.5-100.0 μg/ml, correlation coefficient–0.9995 whereas 
the method was linear in the range of concentrations of API 0.625-
25.0 μg/ml of statins group, correlation coefficient was 0.9990. LOD 
of enalapril was 3.9 ng/ml, while rosuvastatin was 0.03 ng/ml, 
atorvastatin 0.04 ng/ml, simvastatin was 0.02 ng/ml. LOQ was 12 
ng/ml, while rosuvastatin–0.09 ng/ml, atorvastatin–0.1 ng/ml, 
simvastatin–0.07 ng/ml. The developed method was successfully 
applied for the determination of enalapril maleate in the presence of 
API from the group of statins [61, 62]. 
Nagarajan G. et al. proposed the HPLC/UV method for determination 
of enalapril and ramipril in drugs using the chromatographic column 
Oyster BDS C18 column (250x4.6 mm, 5μm) and mobile phase–a 
mixture of buffer solution A (aqueous solution of sodium 
perchloride with the addition of triethylamine, with phosphoric acid 
pH 3.6±0.1 and addition of acetonitrile) and buffer solution B 
(aqueous sodium perchloride solution with addition of 
triethylamine, formation of phosphoric acid pH of 2.6±0.1 and 
addition of acetonitrile) (50:50, v/v), mobile phase rate–1.0 ml/min, 
detection wavelength–208 nm. Enalapril holding time was 4.197 
min, ramiprilum–5.819 min. The method was linear in the range of 
concentrations of 5-30 μg/ml of both analytes, limits of enalapril and 
ramipril detection–0.571 μg/ml and 1.090 μg/ml, respectively, the 
limit of enalapril and ramipril detection–1.733 μg/ml and 3.303 
μg/ml, respectively. The developed method was successfully applied 
for routine analysis of enalapril and ramipril in drugs [63]. 
Scientists Walily A. M., Belal S. F., Heaba E. A., Kersh A. E. described 
the determination of enalapril maleate and hydrochlorothiazide by 
UV spectrophotometry and HPLC/UV methods (mobile phase–a 
mixture of acetonitrile and water (20:80, v/v), detection 
wavelength–215 nm for enalapril and 275 nm for 
hydrochlorothiazide) [64]. 
Scientists Tajerzadeh H. and Hamidi M. developed HPLC/UV 
methods for enalaprilatum determination. The method was linear in 
the range of concentrations of 1-200 μg/ml, LOD of enalaprilatum–
0.125 μg/ml, LOQ of enalaprilatum–0.5 μg/ml. The developed 
method makes it possible to clearly separate the peaks of 
enalaprilatum and enalapril, so it can be used to determine enalapril 
in the presence of enalaprilatum [65]. 
Scientists Uslu B. and Ozden T. proposed HPLC/UV and UHPLC/UV 
methods for enalapril and hydrochlorothiazide determination in 
drugs using chromatographic columns Waters μ-Bondapak C 18 
(300 × 3.9 mm, 10 μm) and Waters Acquity BEH C18 (100 × 2.1 mm, 
1.7 μm). Enalapril holding time by HPLC/UV method was 5.3 min, 
while by UHPLC/UV method was 1.95 min. The HPLC/UV method 
was linear in the range of enalapril concentrations of 0.270-399 
μg/ml and hydrochlorothiazide 0.260-399 μg/ml. The UHPLC/UV 
method was linear in the range of concentrations of enalapril 0.270-
399 μg/ml and hydrochlorothiazide 0.065-249 μg/ml. The 
developed method was successfully applied for the determination of 
enalapril and hydrochlorothiazide in drugs. It can also be used as an 
example of increasing the expressiveness of methods for the 
determination of various APIs [66]. 
Scientists Hossein Danafar and Mehrdad Hamidi described the 
bioanalytical method for enalapril and enalaprilatum in blood 
plasma by the HPLC/MS method using the chromatographic column 
C (18) column and mobile phase–a mixture of methanol, water, 
formic acid (74:24:2 v/v/v), mobile phase rate–0.2 ml/min. Total 
chromatography time was 1.25 min. The method is linear in the 
range of concentrations of 0.1-20 ng/ml of both analytes, the 
correlation coefficient was more than 0.999. LOD was 0.08 ng/ml, 
LOQ was 0.1 ng/ml, respectively. The developed method was 
successfully applied for the determination of enalapril and 
enalaprilatum in blood plasma [67-71]. 
Qi Gu et al. developed the HPLC/MS method for enalapril and 
enalaprilatum detection in blood plasma using the chromatographic 
column Zorbax Extend-C (18). Total chromatography time was 3.5 
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min. The method was linear in the range of concentrations of 0.1-
100.0 ng/ml for both analytes, LOQ–0.1 ng/ml, respectively. The 
developed method was successfully applied for the determination of 
enalapril and enalaprilatum in blood plasma and conducting of 
pharmacokinetic studies [72, 73]. 
Scientists Niopas I., Daftsios A. C., Nikolaidis N. described the 
bioanalytical method of enalapril determination using the developed 
method for study the bioequivalence of two tablet drugs with enalapril 
(Antiprex (Elpen, Greece) and Renitec (Vianex, Greece)) [74]. 
Siddiqui F. A. et al. proposed the HPLC/UV method for the 
determination of metformin in the presence of ACE inhibitors 
(captopril, lisinopril, enalapril) in drugs and the use of developed 
method for the study of pharmacokinetics. Chromatography was 
performed using the chromatography column Purospher® StarRP-
18 endcapped (250 mm x 4.6 mm id) and mobile phase–a mixture of 
methanol and water (50:50 v/v) with the addition of phosphate acid 
to produce pH 3.1, mobile phase rate–1.0 ml/min, and detection 
wavelength–208 nm. The method was linear in the range of 
concentrations of metformin 10-10000 ng/ml and 30-10000 ng/ml 
API from the ACE inhibitors group, correlation coefficient–0.9964. 
The developed method was successfully applied to study the 
pharmacokinetics of metformin, captopril, lisinopril and enalapril 
[75]. 
Among the disadvantages of spectrophotometry, low selectivity, low 
sensitivity and relatively high variability of the results of the analysis 
can be noted. The current review is created with an intended to 
focus on the advantage of HPLC for determination of ACE inhibitors. 
In the design of HPLC and UHPLC techniques, it is necessary to 
consider many factors that will influence the results of the analysis, 
namely the size of the chromatographic column, the type of the 
stationary phase and the size of its particles, the temperature of the 
column, the composition of the mobile phase and the rate of its feed, 
the method of detection, conditions of sample preparation of 
solutions and others The choice of the column type is made taking 
into account the physical and chemical properties of the analyzed 
analytes. Development of chromatographoc conditions for HPLC and 
UHPLC under analytical method development presents on fig. 3. 
 
 
Fig. 3: Development of chromatographoc conditions for HPLC (UHPLC) 
 
Literature survey revealed that a number of methods have been 
reported for estimation of ACE inhibitors individually or in 
combination with other drugs. However, there is very few analytical 
methods reported for the simultaneous analysis of these drugs in a 
combined dosage formulation by HPLC. In additional, analysis of 
approaches to the development of the methods of analysis of ACE 
inhibitors in drugs and biological liquids has been shown that HPLC is 
the most suitable method for analyses ACE inhibitors in substances, 
drugs, biological liquids to performe routine analysis of medicines, 
pharmacokinetic (bioequivalence in vivo), dissolution test for final 
dosages forms (bioequivalence in vitro, biowaiver procedure).  
CONCLUSION  
In light of the benefits discussed in this review, we can conclude that 
analysts are constantly working on developing new methods of 
analysis of ACE inhibitors in drugs and biological liquids and on their 
optimization in order to save time and consumables, which also 
ensures the efficiency of the developed methodology. Among the 
disadvantages of spectrophotometry, low selectivity, low sensitivity 
and relatively high variability of the results of the analysis can be 
noted. Therefore, the advantage is provided by HPLC. Literature 
survey revealed that a number of methods have been reported for 
estimation of ACE inhibitors individually or in combination with 
other drugs. However, there is very few analytical methods reported 
for the simultaneous analysis of these drugs in a combined dosage 
formulation by HPLC. The way of solving the outlined problem lies in 
the plan of creating unified approaches to the development and 
validation of analytical methods of determination, taking into 
account their features, goals and objectives. 
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